A Phase I Dose Escalation Study With Sunitinib (Sutent) in Combination With Capecitabine and Irinotecan (Capiri) in Previously Treated Patients With Advanced Colorectal Cancer.

Trial Profile

A Phase I Dose Escalation Study With Sunitinib (Sutent) in Combination With Capecitabine and Irinotecan (Capiri) in Previously Treated Patients With Advanced Colorectal Cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Sunitinib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Feb 2012 Planned end date changed from 1 Oct 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 25 Mar 2009 Status changed from not yet recruiting to recruiting
    • 13 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top